Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 or placebo plus sintilimab in previously treated advanced hepatocellular carcinoma
CTR20200550Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of IBI310 in hepatocellular carcinoma (HCC), sponsored by Innovent Biologics. Started May 2020; status: completed.
02
Drugs
IBI310
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20200550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200550.